DuraStat

Executive Summary

DuraStat is a privately held medical device company based in San Jose, California, focused on addressing one of the most common complications of spine surgery: iatrogenic durotomy (ID), which occurs in approximately 10% of all spine procedures and up to 25% in certain lumbar revisions. The company's technology aims to provide a reliable dural sealant or repair solution to prevent cerebrospinal fluid leaks, reduce surgical complications, and improve patient outcomes. With spine surgery volumes growing globally, DuraStat's product could capture a significant share of the dural repair market, which remains underserved by current solutions that often lack ease-of-use or effective sealing. The company's early-stage nature and absence of publicly disclosed funding rounds or regulatory milestones suggest it is still in development, but the clinical need and market potential are clear.

Upcoming Catalysts (preview)

• TBDFDA 510(k) clearance or premarket approval for dural sealant70% success
• TBDPublication of pivotal clinical trial results demonstrating superiority over standard of care60% success
• TBDStrategic partnership or distribution agreement with a major spine implant manufacturer50% success